antimyelin antibodies

antimyelin antibodies

Antibodies against myelin oligodendrocyte glycoprotein (MOG) and mylein basic protein (MBP) that are commonly found in people who have had an isolated episode suggesting MULTIPLE SCLEROSIS. Research has shown that people with anti-MOG and anti-MBP antibodies are liable to have relapses of the disease more often and earlier than those without the antibodies. Only 23 per cent of those without the antibodies have the relapse, while 95 per cent of those with the antibodies develop established MS.
References in periodicals archive ?
13-17) Antimyelin antibodies, such as those directed against myelin basic protein (MBP), protein lipid protein (PLP) and myelin oligodendrocyte glycoprotein (MOG), have been variably reported in the serum as well as CSF of patients with MS but also in healthy controls.
Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event.
Such evidence includes the identification of antimyelin antibodies in MS lesions, serum and cerebrospinal fluid (CSF) [59-63], and clinical observations consistent with antibody-mediated demyelination in an MS patient [64].
Antimyelin antibodies do not allow earlier diagnosis of multiple sclerosis.